Trials / Terminated
TerminatedNCT01013818
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Human Genome Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HGS1029 | HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off. |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-11-16
- Last updated
- 2013-08-02
Locations
5 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT01013818. Inclusion in this directory is not an endorsement.